Combined Rituximab + Omalizumab Promising for Refractory BP ...Middle East

Medscape - News
Bullous pemphigoid has high morbidity and mortality, especially in people with comorbidities common to older adults, yet no Food and Drug Administration–approved therapies for BP exist. MDedge News

Hence then, the article about combined rituximab omalizumab promising for refractory bp was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Combined Rituximab + Omalizumab Promising for Refractory BP )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News